These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2891948)

  • 1. Mitozantrone-induced onycholysis.
    Speechly-Dick ME; Owen ER
    Lancet; 1988 Jan; 1(8577):113. PubMed ID: 2891948
    [No Abstract]   [Full Text] [Related]  

  • 2. Mitozantrone-induced onycholysis. A series of five cases.
    Creamer JD; Mortimer PS; Powles TJ
    Clin Exp Dermatol; 1995 Nov; 20(6):459-61. PubMed ID: 8857336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitozantrone-induced onycholysis.
    Mitchell PL; Harvey VJ
    Eur J Cancer; 1992; 28(1):243-4. PubMed ID: 1567671
    [No Abstract]   [Full Text] [Related]  

  • 4. Case reports: mitozantrone-induced onycholysis associated with subungual abscesses, paronychia, and pyogenic granuloma.
    Freiman A; Bouganim N; O'Brien EA
    J Drugs Dermatol; 2005; 4(4):490-2. PubMed ID: 16004024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitozantrone.
    Drug Ther Bull; 1986 Sep; 24(18):71-2. PubMed ID: 3757795
    [No Abstract]   [Full Text] [Related]  

  • 6. Mitoxantrone-induced discoloration of the nails.
    Scheithauer W; Ludwig H; Kotz R; Depisch D
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):763-5. PubMed ID: 2714352
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic milestones. Novantrone (mitozantrone).
    Cotter FE
    Br J Clin Pract; 1988 May; 42(5):207-9. PubMed ID: 3063315
    [No Abstract]   [Full Text] [Related]  

  • 8. [Onycholysis due to docetaxel in breast cancer treatment].
    Grasland A; Grandjean M; Rist S; Bosquet A; Vinceneux P
    Rev Med Interne; 2005 May; 26(5):427-8. PubMed ID: 15893036
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone.
    Stuart-Harris R; Simes RJ; Coates AS; Raghavan D; Devine R; Tattersall MH
    Eur J Cancer Clin Oncol; 1987 May; 23(5):557-61. PubMed ID: 3653179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel-induced onycholysis.
    Prabhash K; Babu KG; Ravi S; Girish MH; Bapsy PP
    J Assoc Physicians India; 2004 Feb; 52():167-8. PubMed ID: 15656060
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy-induced onycholysis.
    Makris A; Mortimer P; Powles TJ
    Eur J Cancer; 1996 Feb; 32A(2):374-5. PubMed ID: 8664062
    [No Abstract]   [Full Text] [Related]  

  • 12. Mitoxantrone induced hyperpigmentation.
    Kumar L; Kochipillai V
    N Z Med J; 1990 Feb; 103(883):55. PubMed ID: 2304701
    [No Abstract]   [Full Text] [Related]  

  • 13. Onycholysis with the appearance of a "sunset" secondary to capecitabine.
    Maino KL; Norwood C; Stashower ME
    Cutis; 2003 Sep; 72(3):234-6. PubMed ID: 14533836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitozantrone--out of the blue.
    Smith G
    Aust Nurses J; 1989 Mar; 18(8):28. PubMed ID: 2730451
    [No Abstract]   [Full Text] [Related]  

  • 15. Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration.
    Roh MR; Cho JY; Lew W
    Yonsei Med J; 2007 Feb; 48(1):124-6. PubMed ID: 17326255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer.
    ten Bokkel Huinink WW; Clavel M; Rodenhuis S; Guastalla JP; Franklin HR; Koier JJ; Vlasveld T; Dalesio O; van Tinteren H; Pinedo HM
    Pathol Biol (Paris); 1992 Nov; 39(9):962. PubMed ID: 1538954
    [No Abstract]   [Full Text] [Related]  

  • 17. An overview of mitozantrone.
    Birchall LA; Bailey NP; Blackledge GR
    Br J Clin Pract; 1991; 45(3):208-11. PubMed ID: 1805919
    [No Abstract]   [Full Text] [Related]  

  • 18. Mitoxantrone salvage in heavily pretreated advanced breast cancer.
    Nathanson L; Williams ME
    Prog Clin Biol Res; 1987; 248():283-7. PubMed ID: 3671416
    [No Abstract]   [Full Text] [Related]  

  • 19. Nail alterations secondary to pactitaxel [corrected] therapy.
    Almagro M; Pozo JD; Garcia J; Vasquez A; Fonseca E
    Eur J Dermatol; 2000 Mar; 10(2):146-7. PubMed ID: 10694317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nail changes secondary to docetaxel (Taxotere).
    Correia O; Azevedo C; Pinto Ferreira E; Braga Cruz F; Polónia J
    Dermatology; 1999; 198(3):288-90. PubMed ID: 10393455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.